References
- Demir, B., Demir, Y., Aksoy, I., Kilic, O. H. T., Gucyetmez, V., & Savas, H. A. (2015). Phenprobamate dependence: A case report. Addictive Behaviors, 45, 232–233. https://doi.org/10.1016/j.addbeh.2015.01.037
- Duzenli, T., Tanoglu, A., Akyol, T., Kara, M., & Yazgan, Y. (2019). Drug-induced liver injury caused by phenprobamate: Strong probability due to repeated toxicity. Euroasian J Hepatogastroenterol, 9(1), 49–51. https://doi.org/10.5005/jp-journals-10018-1295
- Elder, N. C. (1991). Abuse of skeletal muscle relaxants. American Family Physician, 44(4), 1223–1226. https://europepmc.org/article/med/1927837
- Emet, M., Aslan, S., Cakir, Z. G., Uyanik, A., Uzkeser, M., Hacimuftuoglu, A., & Emre, H. (2009). Plasmapheresis is useful in phenprobamate overdose. The American Journal of Emergency Medicine, 27(5), 626. e621-626. e622. https://doi.org/10.1016/j.ajem.2008.08.022
- James, A. O., Nicholson, T. R., Hill, R., & Bearn, J. (2016). Something old, something new: A successful case of meprobamate withdrawal. Case Reports, 2016, bcr2015213606. http://dx.doi.org/10.1136/bcr-2015-213606
- Kumar, M., & Dillon, G. H. (2016). Assessment of direct gating and allosteric modulatory effects of meprobamate in recombinant GABAA receptors. European Journal of Pharmacology, 775, 149–158. https://doi.org/10.1016/j.ejphar.2016.02.031
- Lane, S., Lynn, E., & Shakir, S. (2018). Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open, 8(1), e019759. https://doi.org/10.1136/bmjopen-2017-019759
- Reeves, R. R., Burke, R. S., & Kose, S. (2012). Carisoprodol: Update on abuse potential and legal status. Southern Medical Journal, 105(11), 619. https://doi.org/10.1097/SMJ.0b013e31826f5310
- Tasdemir, H. A., Yildiran, A., Islek, I., Sancak, R., & Dilber, C. (2002). Haemoperfusion may be useful in phenprobamate and polypharmacy intoxication of paediatric patients. Nephrology Dialysis Transplantation, 17(5), 941. https://doi.org/10.1093/ndt/17.5.941
- Tulunay, F., Onaran, H., Ergün, H., Ucar, A., Usanmaz, S., Embil, K., & Tulunay, M. (1998). Pharmacokinetics of phenprobamate after oral administration to healthy subjects. Arzneimittel-Forschung, 48(11), 1068–1071. https://europepmc.org/article/med/9850426
- WebMD. (2018). Do I need a muscle relaxer? WebMD Health Network. Retrieved from https://www.webmd.com/back-pain/do-i-need-a-muscle-relaxer
- Zawertailo, L. A., Busto, U. E., Kaplan, H. L., Greenblatt, D. J., & Sellers, E. M. (2003). Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. Journal of Clinical Psychopharmacology, 23(3), 269–280. https://doi.org/10.1097/01.jcp.0000084031.22282.24